FOSTER CITY, Calif., July 25, 2024 — Gilead Sciences, Inc. today announced the presentation of key data from its innovative HIV treatment portfolio and research pipeline, including a broad range of investigational and marketed agents with varied dosing frequencies and administration methods. The findings presented at the 25th International AIDS Conference (AIDS 2024) reflect a portfolio and future-looking pipeline focused on person-centered drug development strategies to help address unmet needs in HIV treatment.
– New 5-year clinical and real-world data reinforce Biktarvy ® as a long-term treatment option for a diverse range of people with HIV, including those with comorbidities –
– Investigational, once-daily, once-weekly and twice-yearly dosing frequencies across administration methods aim to expand options, advance public health and help address unmet needs in HIV treatment –
Read the full press release here.
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
-
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial
-
New data from EACS 2025 on quality of life and comorbidities in people with HIV
-
IDWeek 2025: Real-world findings show lenacapavir effective in highly treatment-experienced people with HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.